Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session
Retrieved on:
Monday, March 21, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Treatment, Electrophysiology, Private Securities Litigation Reform Act, Biomarker, LinkedIn, Atrial fibrillation, Heart, Left ventricular hypertrophy, Sumathi Best Television Current Reporting Award, ECG, Hypertrophy, Marketing, Risk, Forward-looking statement, HCM, Compliance, Stroke, Research, U.S. Securities and Exchange Commission, Twitter, Goal, LVOT, Facebook, Hypertrophic cardiomyopathy, YouTube, PDUFA, Bristol Myers Squibb, Annual report, Instagram, Blood, Patient, Thrombosis, Security (finance), Silviculture, Liquor, Pharmaceutical industry, Medical device, Diagnosis, MAVACAMTEN, BRISTOL MYERS SQUIBB, MAVACAMTEN, BRISTOL MYERS SQUIBB
Mavacamten has been shown to reduce cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation that results in hypercontractility, left ventricular hypertrophy and reduced compliance.
Key Points:
- Mavacamten has been shown to reduce cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation that results in hypercontractility, left ventricular hypertrophy and reduced compliance.
- Based on data from the EXPLORER-HCM study, the company has a PDUFA date in the U.S. of April 28, 2022.
- Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
- For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .